DUI, Drugs & Driving

Morphine, Heroin and the Horizontal Gaze Nystagmus

September 26th, 2011
Advertisement for curing morphine addictions f...

In the past years, my office has seen an increase in the number of “drugged” driving cases we receive. While arrests for marijuana make up the vast majority of those cases, we are also seeing a dramatic rise in prescription drug cases along with traffic stops implicating harder drugs such morphine and heroin.

As with other impaired driving cases, it is vital that you know the observations that would be consistent with impairment by that drug.  It is also vital that you determine if the “standardized field sobriety test” protocol adopted in Ohio is applicable in recognizing clues of impairment due to that specific drug.  The National Highway Traffic Safety Administration (hereinafter NHTSA) has been at the forefront in research to this very point.  The information in this article is derived from the NHTSA Drug and Human Performance Fact Sheet.

Heroin and Morphine are both classified as narcotic analgesics.  Morphine is a naturally occurring substance extracted from the seedpod of the poppy plant, Papavar somniferum. The milky resin that seeps from incisions made in the unripe seedpod is dried and powdered to make opium, which contains a number of alkaloids including morphine. Morphine concentration in opium can range from 4-21%. An alternate method of harvesting morphine is by the industrial poppy straw process of extracting alkaloids from the mature dried plant, which produces a fine brownish powder. Morphine is a schedule II controlled substance and is available in a variety of prescription forms: injectables (0.5-25 mg/mL strength); oral solutions (2-20 mg/mL); immediate and controlled release tablets and capsules (15-200 mg); and suppositories (5-30 mg). Heroin is a schedule I controlled substance and is produced from morphine by acetylation at the 3 and 6 positions. The majority of heroin sold in the U. S. originates from Southeast Asia, South America (Columbia) and Mexico. Low purity Mexican black tar heroin is most common on the West coast, while high purity Columbian heroin dominates in the East and most mid-western states.

Depending on the morphine dose and the route of administration, onset of effects is within 15-60 minutes and effects may last 4-6 hours. The duration of analgesia increases progressively with age although the degree of analgesia remains unchanged. Following heroin use, the intense euphoria lasts from 45 seconds to several minutes, peak effects last 1-2 hours, and the overall effects wear off in 3-5 hours, depending on dose.

The drug manufacturer states that morphine may impair the mental and/or physical abilities needed to perform potentially hazardous activities such as driving a car, and patients must be cautioned accordingly. Driving ability in cancer patients receiving long-term morphine analgesia (mean 209 mg daily) was considered not to be impaired by the sedative effects of morphine to an extent that accidents might occur. There were no significant differences between the morphine treated cancer patients and a control group in vigilance, concentration, motor reactions, or divided attention. A small but significant slowing of reaction time was observed at 3 hours. In several driving under the influence case reports, where the subjects tested positive for morphine and/or 6-acetylmorphine, observations included slow driving, weaving, poor vehicle control, poor coordination, slow response to stimuli, delayed reactions, difficultly in following instructions, and falling asleep at the wheel.  Classification of risk depends on tolerance, dose, time of exposure, acute or chronic use, presence or absence of underlying pain, physiological status of individual, and the presence of other drugs: moderately to severely impairing in non-tolerant individuals; mild to moderately impairing if morphine is used as medication on a regular basis for chronic pain; severely impairing in acute situations if used orally, or as an intravenous medication, or if either drug is taken illicitly.

With regard to the standardized field sobriety tests, law enforcement will be required to rely on the coordination tests rather than the horizontal gaze nystagmus test.  Horizontal gaze nystagmus is not present; vertical gaze nystagmus is not present; lack of convergence is not present; pupil size is constricted; little or no reaction to light; pulse rate down; blood pressure down; body temperature down. Other characteristic indicators may include presence of fresh injection marks, track marks, flaccid muscle tone, droopy eyelids, drowsiness or “on-the-nod”, and low raspy slow speech.

Charles M. Rowland II has dedicated his practice to representing the accused drunk driver.  His commitment includes continuous study of the forensic sciences and legal strategies that will help you win your DUI case.  If you find yourself in need of a qualified and experienced Ohio OVI attorney, CONTACT Charles M. Rowland II at (937) 318-1DUI or 1-888-ROWLAND.

Illegal Bath Salts, A Primer

September 7th, 2011

Methylenedioxypyrovalerone (MDPV) (“bath salts”, “Ivory Wave”, “plant fertilizer”, “plant food”,“Vanilla Sky”, “Energy-1”)

Methylenedioxypyrovalerone (MDPV) is a designer drug of the phenethylamine class. MDPV is structurally related to cathinone, an active alkaloid found in the khat plant, methamphetamine, and methylenedioxymethamphetamine (MDMA). MDPV is a central nervous system (CNS) stimulant and it was first seized in Germany in 2007. The abuse of MDPV is increasing, particularly in Europe and Australia. MDPV has been identified in products called “bath salts” which are sold on websites based in Europe.  MDPV is not approved for medical use in the United States.

MDPV (1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)- 1-pentanone; Chemical Abstract Service Number 687603- 66-3) is related in chemical structure to schedule I hallucinogenic substances (MDMA, MDEA) and to schedule I stimulants (cathinone, methcathinone). Its molecular formula is C16H21NO3 and its molecular weight is 275 g/mol. MDPV has a high melting point (estimated at 200oC) and is a solid at room temperature. MDPV is structurally related to MDMA and also to cathinone, with a ring-bearing substituent group. Cathinone derivatives, which bear ring-group substituents, have been reported to induce subjective effects similar to those induced by cocaine, amphetamine, and MDMA in humans. The subjective effects induced by ring-group substituted cathinones are feelings of empathy, stimulation, alertness, euphoria, and awareness of senses.  It has been demonstrated that MDPV administered to mice increased the extracellular levels of dopamine levels 60 min after administration of MDPV. Though MDPV increased dopamine levels, the effect was not as marked as the increases induced by methamphetamine or MDMA. (March 2011 DEA/OD/ODE)

Users of MDPV anecdotally report that they take 5 mg or less per session and there have been reports of cravings for MDPV by users. The acute side effects of MDPV include tachycardia, hypertension, vasoconstriction, and sweating. The duration of the subjective effects is about 3 to 4 hours and the side effects continuing a total of 6 to 8 hours after administration. Higher doses of MDPV have caused intense, prolonged panic attacks in stimulant-intolerant users. Users have reported bouts of psychosis induced by sleep deprivation and becoming addicted after using higher doses or using at more frequent dosing intervals. MDPV loses potency when it is put into solution.  MDPV has been identified in a seized product called “Ivory Wave”. It is sold as a “bath salt” with the label indicating “for novelty use only” without any instructions for dosage. “Ivory Wave” is sold in 500 mg packets on Internet sites based in Europe. MDPV has also been identified in a product called “Energy 1”, which is sold on United Kingdom- based websites.  User population information in the U.S. is very limited. There have been reports of MDVP being used predominantly by the youth population. MDPV data are not reported by any national drug study programs.

Currently, MDPV is not a scheduled drug under the Controlled Substances Act (CSA).

Information in this post is taken from information provided by the Drug Enforcement Administration, Office of Diversion. Orginal link here: http://www.deadiversion.usdoj.gov/drugs_concern/mdpv.pdf

Dayton DUI attorney Charles M. Rowland II dedicates his practice to defending the accused drunk driver.  He has the credentials and the experience to win your case and has made himself Dayton’s choice for DUI defense.  Contact Charles Rowland by phone at 937-318-1DUI (937-318-1384), 937-879-9542, or toll-free at 1-888-ROWLAND (888-769-5263).  For after-hours help contact our 24/7 DUI HOTLINE at 937-776-2671.  For information about Dayton DUI sent directly to your mobile device, text DaytonDUI (one word) to 50500.  Follow DaytonDUI on Twitter @DaytonDUI or Get Twitter updates via SMS by texting DaytonDUI to 40404. DaytonDUI is also available on Facebook, www.facebook.com/daytondui.  You can also email Charles Rowland at: CharlesRowland@CharlesRowland.com or write to us at 2190 Gateway Dr., Fairborn, Ohio 45324.

Driving Under the Influence of Drugs in Ohio

August 31st, 2011
Cocaine hydrochloride for medicinal use. This ...

Ohio Revised Code 4511.19(A)(1)(j) prohibits the operation of a motor vehicle under the influence of a controlled substance, specifically if your blood or urine contains a statutorily specified concentration of: amphetamine, cocaine, cocaine metabolite, heroin, heroin metabolite (6-monoacetyl morphine), L.S.D., marijuana, marijuana metabolite, methamphetamine, phencyclidine, salvia divinorum, or salvinorin A.

Dayton DUI Attorney Charles M. Rowland II dedicates himself to the defense of the accused drunk driver.  He has attended the latest forensic science seminar of the National College for DUI Defense and is the only Ohio OVI attorney to have earned certification in Forensic Sobriety Assessment.  If you need an aggressive Ohio DUI attorney, contact Charles M. Rowland II today HERE, or at 937-318-1DUI (318-1384) or visit www.DaytonDUI.com.

Driving Under the Influence of Ecstasy

July 5th, 2011

Driving Under the Influence of Drugs in Ohio

Animated picture of the chemical structure of ...

“Ecstasy,” 3,4-Methylenedioxymethamphetamine (MDMA) is popular among recreational drug users ages 17-25 who take the drug to experience heightened responsiveness to intimate touch, increased sexual stimulation, increased energy, elevated self-esteem and euphoria.  Several recent studies have attempted to define MDMA/ecstasy impairment:

  • Nichols, “Differences Between the Mechanism of Action of MDMA, MBB and the Classic Hallucinogens, Identification of a New Therapeutic Class: Entactogens,” 18 J. Psychoactive Drugs 305 (1986);
  • Parrott & Lasky, “Ecstasy (MDMA) Effects Upon Mood and Cognition: Before, During and After a Saturday Night Dance,” 139 Psychopharmacology, 261 (1998);
  • McCann et al., “Cognitive Performance in (+3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)) Users: A Controlled Study,” 143 Psychopharmacology 417 (1999);
  • Gauzoulis-Mayfrank, et al., “Impaired Cognitive Performance in Drug-Free Users of Recreational Ecstasy (MDMA),” 68 J. Neurol. Neurosurg. Psych. 719 (2000);

Assuming your client does not take a chemical test, these types of case are defensible.  Because Ohio does not employ a Drug Recognition Expert (DRE) protocol, you can use a lack of “indicators” for ecstasy with little chance that the officer can present evidence based on any specialized training to contradict you.  Employing an expert should have particular impact in these types of cases.  Often the indicators for alcohol come in conflict with the “indicators” for MDMA use.  The indicators for MDMA include:

  • Horizontal and vertical gaze not present;
  • No lack of convergence;
  • Dilated pupils with slow reaction to light;
  • Elevated pulse rate;
  • Elevated blood pressure; and
  • Elevated body temperature.

Drug Evaluation and Classification Training Program – The Drug Recognition Expert School, U.S. Department of Transportation Safety Institute, NHTSA 1999 ed, as cited in Barone, Defending Drinking Drivers, Second ed. at 1-103.  Challenging this evidence at a motion to suppress would also require the prosecution to bring in an expert witness as the typical officer would lack the scientific background to present psychopharmalogical evidence.  You should also focus your potential defenses on what the officer observed as indicators of impairment by MDMA and the typical defenses raised by creating a time line favorable to your client.

If you face a charge of driving under the influence of drugs or driving under the influence of ecstasy, contact Dayton DUI Attorney Charles M. Rowland II at 937-318-1DUI (318-1384), 1-888-ROWLAND (888-769-5263) or visit www.DaytonDUI.com.

Salvia Divinorum, A Primer

April 25th, 2011
salvia divinorum in d.c.
Image by oceandesetoiles via Flickr

Salvia divinorum is a perennial herb in the mint family native to certain areas of the Sierra Mazateca region of Oaxaca, Mexico. The plant, which can grow to over three feet in height, has large green leaves, hollow square stems and white flowers with purple calyces, can also be grown successfully outside of this region . Salvia divinorum has been used by the Mazatec Indians for its ritual divination and healing. The active constituent of Salvia divinorum has been identified as salvinorin A. Currently, neither Salvia divinorum nor any of its constituents, including salvinorin A, are controlled under the federal Controlled Substances Act (CSA). However, the abuse of Salvia Divinorum is gaining popularity in the United States, particulary by adolescents and young adults.

A limited number of studies have reported the effects of using either plant material or salvinorin A. Psychic effects include perceptions of bright lights, vivid colors and shapes, as well as body movements and body or object distortions. Other effects include dysphoria, uncontrolled laughter, a sense of loss of body, overlapping realities, and hallucinations (seeing objects that are not present). Adverse physical effects may include incoordination, dizziness, and slurred speech.

Scientific studies show that salvinorin A is a potent and selective kappa opioid receptor agonist. Other drugs that act at the kappa opioid receptor also produce hallucinogenic effects and dysphoria similar to that produced by salvinorin A. Salvinorin A does not activate the serotonin 2A receptor, which mediates the effects of other schedule I hallucinogens.  Due to the hallucinogenic effects there is a substantial risk of injury or death as a result of impaired judgment due to disruptions of sensory and cognitive functions

According to a National Survey on Drug Use and Health Report published by SAMHSA in February 2008, it is estimated that 1.8 million persons aged 12 or older used Salvia divinorum in their lifetime, a approximately 750,000 did so in the past year. Use was more common among young adults (18 to 25 years old) as opposed to older adults (>26 years of age). Young adults were 3 times more likely than youths aged 12 to 17 to have used Salviadivinorum in the past year. Use is more common in males than females.

The Drug Enforcement Administration has prepared this report on salvia divinorum.  You can find the original materials here: http://www.justice.gov/dea/concern/salvia_divinorum.html.  If you find yourself in need of an Ohio DUI attorney, contact Charles M. Rowland II at (937) 879-9542 or visit www.DaytonDUI.com.